Chemotherapy-induced Nausea and Vomiting
Conditions
Keywords
brain stimulation, tDCS, nausea and vomiting
Brief summary
this work is looking for the effect of tDCS of the motor cortex on the chemotherapy induced nausea and vomiting in cancer breast patients
Detailed description
Chemotherapy has played an important role in improving patient outcomes in oncology and is a cornerstone of therapy for most patients with cancer. Of the adverse effects, none is more feared than chemotherapy-induced nausea and vomiting (CINV). Nausea and vomiting can adversely affect patients' quality of life and make it difficult for them to perform their activities of daily living. Uncontrolled CINV can give rise to medical complications, including poor nutrition, dehydration, electrolyte imbalances, and physical and mental deterioration.The introduction and development of antiemetic drugs have significantly improved the ability of clinicians to control CINV. The mainstays of antiemetic therapy include serotonin (5-HT3) receptor antagonists (RAs) and neurokinin 1 (NK-1) RAs. Researchers and patients are seeking additional methods of controlling CINV, such as non-drug therapies. Transcranial direct current stimulation (tDCS) is a relatively simple technique requiring only a few parts.
Interventions
DEVICEtDCS
a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
DEVICEsham tDCS
sham tDCS
Sponsors
Shereen Mamdouh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* breast cancer therapy receiving anthracyclin based adjuvant chemotherapy and prophylaxis against nausea and vomiting
Exclusion criteria
* patients with intracranial metallic devices or with pacemakers or any other device. * patients with extensive myocardial ischemia * patients known to have epilepsy patients refusal.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative of nausea scoring | the first 72 hours after the infusion of chemotherapy | 0=None 1. Loss of appetite eout alternation in eating habits 2. Dec. oral intake eout significant wgt loss, dehydration or malnutrion 3. Iv fluids, tube feeding, TPN 4. Life threatening consequence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cumalative vomiting scoring | the first 72 hours after the infusion of chemotherapy | 0= None 1=1 episode in 24h 2= 2-5 episodes in 24h 3=More 6 episodes in 24h 4=Life threatening consequence |
Countries
Egypt
Outcome results
None listed